FDA steps in after a patient on Antares' 'low-T' drug breaks out in hives January 13, 2015 | By Damian Garde

The FDA wants more safety data on Antares Pharma's ($ATRS) testosterone treatment after noting a case of hives in a clinical trial, presenting a costly delay for the company's plans to hit the market.
more